Using Ch25h-/- mice and a high-dose LPS lung injury model, the study shows that 25-hydroxycholesterol promotes endothelial activation and vascular leak via an LXR-independent mechanism.
JCI Insight · 15 authors, 6 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
Using Ch25h-/- mice and a high-dose LPS lung injury model, the study shows that 25-hydroxycholesterol promotes endothelial activation and vascular leak via an LXR-independent mechanism.
The paper investigates 25-hydroxycholesterol (25HC) produced by cholesterol-25-hydroxylase (CH25H) in a high-dose LPS mouse model of acute lung injury. Sustained reductions in BALF cytokines and microvascular leak were observed in Ch25h-/- mice compared with wild-type, whereas LXR-null mice did not show this protection, implicating an LXR-independent pathway. Systemically delivered 25HC was sufficient to induce lung Vcam1 and increase endothelial monolayer permeability but did not by itself cause BALF protein leak in naive mice, suggesting a required proinflammatory milieu. Bone marrow chimera experiments indicated that non-hematopoietic rather than hematopoietic CH25H drives vascular leak. An association between alveolar macrophage CH25H expression and ARDS severity markers is reported in human patients, although the human data are observational. Limitations include reliance on a single LPS model, imperfect selectivity of the ER stress inhibitor PBA, in vitro 25HC supplementation that does not model native CH25H/25HC, and lack of endothelial-specific Ch25h deletion. The authors propose ER stress as a candidate integrator of context-dependent 25HC effects.